Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation

Daley, Alexandra; Randall, Roger; Darsley, Michael; Choudhry, Naheed; Thomas, Nicola; Sanderson, Ian R.; Croft, Nick M.; Kelly, Paul
November 2007
Gut;Nov2007, Vol. 56 Issue 11, p1550
Academic Journal
Objective: Enterotoxigenic Escherichia coli (ETEC) is a major cause of acute diarrhoea in children in the developing world, in travellers and in the military. Safe, effective vaccines could reduce morbidity and mortality. As immunity to ETEC is strain specific, the ability to create vaccines in vitro which express multiple antigens would be desirable. It was hypothesised that three genetically attenuated ETEC strains, one with a genetic addition, would be immunogenic and safe, and they were evaluated in the first licensed UK release of genetically modified oral vaccines. Methods: Phase 1 studies of safety and immunogenicity were carried out at a Teaching Hospital in London. Varying oral doses of any of three oral vaccines, or placebo, were administered to volunteers of both sexes (n = 98). Peripheral blood responses were measured as serum antibodies (IgG or IgA) by ELISA, antibody- secreting cell (ASC) responses by enzyme-linked immunospot (ELISPOT), and antibody in lymphocyte supernatant (ALS) by ELISA. Mucosal antibody secretion was measured by ELISA for specific IgG and IgA in whole gut lavage fluids (WGLFs). Results: Significant mucosal IgA responses were obtained to colonisation factors CFA/I, CS1, CS2 and CS3, both when naturally expressed and when genetically inserted. Dose-response relationships were most clearly evident in the mucosal IgA in WGLF. Vaccines were well tolerated and did not elicit interleukin (IL) 8 or IL6 secretion in WGLF. Conclusions: Genetically modified ETEC vaccines are safe and induce significant mucosal IgA responses to important colonisation factors. Mucosal IgA responses were clearly seen in WGLF, which is useful for evaluating oral vaccines.


Related Articles

  • Surface-displayed viral antigens on Salmonella carrier vaccine. Lee, Jong-Soo; Shin, Kwang-Soon; Pan, Jae-Gu; Kim, Chul-Joong // Nature Biotechnology;Jun2000, Vol. 18 Issue 6, p645 

    We have developed a recombinant live oral vaccine using the ice-nucleation protein (Inp) from Pseudomonas syringae to display viral antigens on the surface ofSalmonella spp. Fusion proteins containing viral antigens were expressed in the oral vaccine strain,Salmonella typhi Ty21a. Surface...

  • Phytol-based novel adjuvants in vaccine formulation: 2. assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. So-Yon Lim; Bauermeister, Adam; Kjonaas, Richard A.; Ghosh, Swapan K. // Journal of Immune Based Therapies & Vaccines;2006, Vol. 4, p5 

    Background: Adjuvants are known to significantly enhance vaccine efficacy. However, commercial adjuvants often have limited use because of toxicity in humans. The objective of this study was to determine the comparative effectiveness of a diterpene alcohol, phytol and its hydrogenated derivative...

  • The Biology of Oral Tolerance and Issues Related to Oral Vaccine Design. Poonam, Poonam // Current Pharmaceutical Design;Jul2007, Vol. 13 Issue 19, p2001 

    Intestinal tissues are continuously exposed to tremendous amount of foreign material, either beneficial or harmful. Although strong protective immune responses are required to clear harmful pathogen infections, similar responses against food antigen can lead to harmful inflammation. Therefore,...

  • E. coli vaccine.  // BEEF;Apr2011, Vol. 47 Issue 8, p88 

    The article reports on the availability of E. coli Bacterial vaccine with SRP® technology from Pfizer Animal Health.

  • Herd Health News.  // Indiana Prairie Farmer;Mar2011, Vol. 185 Issue 3, pBP9 

    The article offers news briefs related to herd health which include the development of treatments against the cattle fever thick that causes Texas fever, the availability of E.coli Bacterial Extract vaccine with SRP technology, and the expansion of Express FP 5-VL5 vaccine' label against...

  • Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Villena, Julio; Medina, Marcela; Vintiñi, Elisa; Alvarez, Susana // Canadian Journal of Microbiology;Aug2008, Vol. 54 Issue 8, p630 

    This work demostrates that nonrecombinant Lactococcus lactis NZ, administered by the oral route at the proper dose, is able to improve resistance against pneumococcal infection. Lactococcus lactis NZ oral administration was able to improve pathogen lung clearance, increased survival of infected...

  • Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model. Guo, Le; Liu, Kunmei; Xu, Guangxian; Li, Xiaokang; Tu, Jiajie; Tang, Feng; Xing, Yingying; Xi, Tao // Applied Microbiology & Biotechnology;Sep2012, Vol. 95 Issue 6, p1437 

    Epitope vaccine based on the enzyme urease of Helicobacter pylori is a promising option for prophylactic and therapeutic vaccination against H. pylori infection. In our previous study, the epitope vaccine CTB-UA, which was composed of the mucosal adjuvant cholera toxin B subunit (CTB) and an...

  • Edible vaccine. Arntzen, Charles J. // Public Health Reports;May/Jun97, Vol. 112 Issue 3, p190 

    Presents an interdisciplinary research linking immunology and plant molecular biology has led to the creation of genetically engineered plants whose edible parts contain proteins that can functions as oral vaccines. Advantage of the technology; Objectives for conducting the research; Frontiers...

  • Jabs fight death after dinner. Coghlan, Andy // New Scientist;02/21/98, Vol. 157 Issue 2122, p20 

    Reports on a prototype vaccine which was developed by the National Institute of Child Health and Human Development in Bethesda, Maryland, which protects against Escherichia coli 0157, a food-borne disease. Details on the vaccine; Comments from Duane Alexander, director of the institute.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics